Clinical-stage drug developer QurAlis has received European regulatory clearance for its precision therapeutic product candidate, QRL-201, for the treatment of amyotrophic lateral sclerosis (ALS). The company plans to initiate a Phase I clinical trial of QRL-201 in participating European Union countries by Q4 2023.

QRL-201 aims to restore the expression of STATHMIN-2 (STMN2) in ALS patients, which the company claims is the first therapy to do so. STMN2 is an important protein for neural repair and axonal stability. The clinical trial will assess the safety, tolerability, and pharmacokinetics of QRL-201 in ALS patients. The company's global regulatory strategy for QRL-201 includes obtaining clearance from the European Clinical Trial Authorisation and the Canadian Clinical Trial Authorisation.

QurAlis is a biotech company that is focused on developing precision medicine for ALS and related neurodegenerative diseases. The company has a total of five drugs in development, one of which is QRL-201, a treatment that restores the production of the STMN2 protein in individuals with ALS. Another drug, QRL-101, aims to address the progression of hyperexcitability-related diseases in ALS patients. Both QRL-201 and QRL-101 are currently undergoing Phase I clinical trials.